Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

Abstract

Lipoprotein apheresis (LA) is currently the most powerful intervention possible to reach a maximal reduction of lipids in patients with familial hypercholesterolemia and lipoprotein(a) hyperlipidemia. Although LA is an invasive method, it has few side effects and the best results in preventing further major cardiovascular events. It has been suggested that the highly significant reduction of cardiovascular complications in patients with severe lipid disorders achieved by LA is mediated not only by the potent reduction of lipid levels but also by the removal of other proinflammatory and proatherogenic factors. Here we performed a comprehensive proteomic analysis of patients on LA treatment using intra-individually a set of differently sized apheresis filters with the INUSpheresis system. This study revealed that proteomic analysis correlates well with routine clinical chemistry in these patients. The method is eminently suited to discover new biomarkers and risk factors for cardiovascular disease in these patients. Different filters achieve reduction and removal of proatherogenic proteins in different quantities. This includes not only apolipoproteins, C-reactive protein, fibrinogen, and plasminogen but also proteins like complement factor B (CFAB), protein AMBP, afamin, and the low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) among others that have been described as atherosclerosis and metabolic vascular diseases promoting factors. We therefore conclude that future trials should be designed to develop an individualized therapy approach for patients on LA based on their metabolic and vascular risk profile. Furthermore, the power of such cascade filter treatment protocols may improve the prevention of cardiometabolic disease and its complications.

Key words

extracorporal apheresis - proteomics analysis - cardiovascular risk factors - precision medicine

Publication History

Received: 15 January 2022

Accepted after revision: 15 February 2022

Article published online:
12 April 2022

• References

• 1 Heigl F, Pflederer T, Klingel R. et al. Lipoprotein apheresis in Germany - Still more commonly indicated than implemented. How can patients in need access therapy?. Atheroscler Suppl 2019; 40: 23-29
• 2 Klingel R, Heigl F, Schettler V. et al. Lipoprotein(a) – Marker for cardiovascular risk and target for lipoprotein apheresis. Atheroscler Suppl 2019; 40: 17-22
• 3 Weiss N, Julius U. Lipoprotein(a) apheresis in patients with peripheral arterial disease: rationale and clinical results. Clin Res Cardiol Suppl 2019; 14: 39-44
• 4 Julius U, Kuss S, Tselmin S. et al. Why some patients undergoing lipoprotein apheresis therapy develop new cardiovascular events?. J Cardiovasc Dev Dis 2020; 7
• 5 Dargent A, Pais de Barros JP, Saheb S. et al. LDL apheresis as an alternate method for plasma LPS purification in healthy volunteers and dyslipidemic and septic patients. J Lipid Res 2020; 61: 1776-1783
• 6 Tselmin S, Schmitz G, Julius U. et al. Acute effects of lipid apheresis on human serum lipidome. Atheroscler Suppl 2009; 10: 27-33
• 7 Eliaz I, Weil E, Dutton JA. et al. Lipoprotein apheresis reduces circulating galectin-3 in humans. J Clin Apher 2016; 31: 388-392
• 8 Kobayashi S, Oka M, Moriya H. et al. LDL-apheresis reduces P-Selectin, CRP and fibrinogen – possible important implications for improving atherosclerosis. Ther Apher Dial 2006; 10: 219-223
• 9 Otto C, Geiss HC, Empen K. et al. Long-term reduction of C-reactive protein concentration by regular LDL apheresis. Atherosclerosis 2004; 174: 151-156
• 10 Schettler V, Wieland E. Effects of LDL-apheresis-more than reduction of cholesterol?. Dtsch Med Wochenschr 2007; 132: 575-578
• 11 Yuasa Y, Osaki T, Makino H. et al. Proteomic analysis of proteins eliminated by low-density lipoprotein apheresis. Ther Apher Dial 2014; 18: 93-102
• 12 Thompson GR, Barbir M, Davies D. et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208: 317-321
• 13 Rizos CV, Skoumas I, Rallidis L. et al. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. Int J Cardiol 2021; 345: 119-124
• 14 Coan PM, Barrier M, Alfazema N. et al. Complement factor B is a determinant of both metabolic and cardiovascular features of metabolic syndrome. Hypertension 2017; 70: 624-633
• 15 Ji FP, Wen L, Zhang YP. et al. Serum complement factor B is associated with disease activity and progression of idiopathic membranous nephropathy concomitant with IgA nephropathy. Int Urol Nephrol 2021; Online ahead of print
• 16 Lu H, Guo P. Plasma heparin cofactor II activity correlates with the incidence of in-stent restenosis after the intervention of arteriosclerosis obliterans in lower extremity. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2015; 40: 177-181
• 17 Murray H, Qiu B, Ho SY. et al. Complement factor B mediates ocular angiogenesis through regulating the VEGF signaling pathway. Int J Mol Sci 2021; 22
• 18 Matsunaga H, Iwashita M, Shinjo T. et al. Adipose tissue complement factor B promotes adipocyte maturation. Biochem Biophys Res Commun 2018; 495: 740-748
• 19 Carruthers NJ, Strieder-Barboza C, Caruso JA. et al. The human type 2 diabetes-specific visceral adipose tissue proteome and transcriptome in obesity. Sci Rep 2021; 11: 17394
• 20 Ngo LH, Austin Argentieri M, Dillon ST. et al. Plasma protein expression profiles, cardiovascular disease, and religious struggles among South Asians in the MASALA study. Sci Rep 2021; 11: 961
• 21 Varga VE, Lőrincz H, Szentpéteri A. et al. Changes in serum afamin and vitamin E levels after selective LDL apheresis. J Clin Apher 2018; 33: 569-575
• 22 Kurdiova T, Balaz M, Kovanicova Z. et al. Serum afamin a novel marker of increased hepatic lipid content. Front Endocrinol (Lausanne) 2021; 12: 670425
• 23 Lorenzo-Almorós A, Hang T, Peiró C. et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. Cardiovasc Diabetol 2019; 18: 140
• 24 Kollerits B, Lamina C, Huth C. et al. Plasma concentrations of afamin are associated with prevalent and incident type 2 diabetes: a pooled analysis in more than 20,000 individuals. Diabetes Care 2017; 40: 1386-1393
• 25 Karlsson C, Wallenius K, Walentinsson A. et al. Identification of proteins associated with the early restoration of insulin sensitivity after biliopancreatic diversion. J Clin Endocrinol Metab 2020; 105: e4157-e4168
• 26 Kaburagi Y, Takahashi E, Kajio H. et al. Urinary afamin levels are associated with the progression of diabetic nephropathy. Diabetes Res Clin Pract 2019; 147: 37-46
• 27 Kheiripour N, Khodamoradi Z, Ranjbar A. et al. The positive effect of short-term nano-curcumin therapy on insulin resistance and serum levels of afamin in patients with metabolic syndrome. Avicenna J Phytomed 2021; 11: 146-153
• 28 Huang Y, Yin H, Wang J. et al. Aberrant expression of FcγRIIIA (CD16) contributes to the development of atherosclerosis. Gene 2012; 498: 91-95
• 29 Gavasso S, Nygård O, Pedersen ER. et al. Fcgamma receptor IIIA polymorphism as a risk-factor for coronary artery disease. Atherosclerosis 2005; 180: 277-282
• 30 Masuda M, Miyoshi H, Kobatake S. et al. Increased soluble FcgammaRIIIa (Mphi) in plasma from patients with coronary artery diseases. Atherosclerosis 2006; 188: 377-383
• 31 Liu H, Luo D, Qiu Y. et al. The effect of AMBP SNPs, their haplotypes, and gene-environment interactions on the risk of atherothrombotic stroke among the Chinese population. Genet Test Mol Biomarkers 2019; 23: 487-494
• 32 Gertow J, Ng CZ, Mamede Branca RM. et al. Altered protein composition of subcutaneous adipose tissue in chronic kidney disease. Kidney Int Rep 2017; 2: 1208-1218
• 33 Ushakov RE, Aksenov ND, Pugovkina NA. et al. Effects of IGFBP3 knockdown on human endometrial mesenchymal stromal cells stress-induced senescence. Biochem Biophys Res Commun 2021; 570: 143-147
• 34 Peters KE, Xu J, Bringans SD. et al. PromarkerD predicts renal function decline in type 2 diabetes in the canagliflozin cardiovascular assessment study (CANVAS). J Clin Med 2020; 9: 3212
• 35 Li J, Liu X, Xiang Y. et al. Alpha-2-macroglobulin and heparin cofactor II and the vulnerability of carotid atherosclerotic plaques: An iTRAQ-based analysis. Biochem Biophys Res Commun 2017; 483: 964-971
• 36 Rau JC, Deans C, Hoffman MR. et al. Heparin cofactor II in atherosclerotic lesions from the pathobiological determinants of atherosclerosis in youth (PDAY) study. Exp Mol Pathol 2009; 87: 178-183